No Data
Monte Rosa Therapeutics Promotes Champoux to COO
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Immunovant (IMVT) and Monte Rosa Therapeutics (GLUE)
Express News | Monte Rosa Therapeutics Announces Leadership Team Promotions
Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today an
Wedbush Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $11
Wedbush analyst Robert Driscoll maintains $Monte Rosa Therapeutics(GLUE.US)$ with a buy rating, and maintains the target price at $11.According to TipRanks data, the analyst has a success rate of 43.8
Express News | Wedbush Reiterates Outperform on Monte Rosa Therapeutics, Maintains $11 Price Target